



## **GYN PATHOLOGY REQUISITION**

For Lab Use Only DO NOT place anything or write in this space.

| PATIENT INFORMATION   |  | CLINICIAN INFORMATION   |
|---|--|---|
| LAST NAME   | 1  |   |
| FIRST NAME  |  |   |
| MIDDLE NAME   |  |   |
| DATE OF BIRTH (MM/DD/YYYY) PATIENT MRN  |  |   |
| TELEPHONE NUMBER  |  |   |
| SEX   |  |   |
| ☐ Female ☐ Male ☐ Other/Unknown   |  |   |
| STREET NUMBER STREET NAME APT NUMBER  |  |   |
| CITY STATE ZIP  | the patient has given consent as required ur   | t information has been provided to the patient about the test(s) to be performed and<br>nder applicable laws and regulations for the test(s) to be performed. The test(s) to be   |
|   | patient. I confirm that the person listed as the   | results will be used for medical management and treatment decision purposes for this<br>Ordering Clinician is authorized by law to order the tests(s) requested herein.   |
| ACKNOWLEDGEMENT: I authorize the laboratory to provide to my health plan the information on this form and other information by my healthcare provider if necessary for reimbursement. I understand that the laboratory may seek prior author  | ization REQUIRED   | SIGNATURE DATE (MM/DD/YY)   |
| for testing from my health plan on my behalf. I also authorize all benefits of the plan to be payable directly to the laboratory agree to remit to the laboratory any payment for these services made directly to me. I understand that the laboratory may  | be an  | BILLING INFO  |
| out-of-network provider for my health plan and that I may be responsible for all amounts not reimbursed by my health plan. I designate the laboratory as my Authorized Representative, as provided under ERISA, 29 C.F.R. § 2560.5031 (b)(4), and/or  | as my DILL INCLIDANCE Attach logible f   | ront and back copy of insurance cards.  |
| Attorney in Fact, for the purpose of pursuing administrative appeals to which I am entitled and, if the laboratory deems it approany legal and/or equitable claims that I could bring against my health plan, and/or its fiduciaries, and/or its administrator  | priate,  |   |
| respect to their handling or resolution of my insurance claim.  PATIENT SIGNATURE  DATE (MM/DD/YY)  | IPA NAME   |   |
| X   |  |   |
| SPECIMEN INFORMATION - REQUIRED   | MEMBER ID  |   |
|   | BILL PATIENT (Cash pay, no insura  | ance)   |
| Collected on: Time:     AM PN   | CLIENT BILL  | ,   |
| DIAGNOSTIC INFORMAT   | ION (ICD-10) (Check all that apply)  |   |
| MEDICARE SCREENING - See Medicare Section & Sign Advance Beneficiary Notice of Nonco  | •  |   |
|   | Z34.81 Enctr suprvn norm preg, 1st tri. Z34.82 Enctr suprvn norm preg, 2nd tri.  | ☐ Z12.72 Enctr screen malig. neo. vagina ☐ Z34.00 Enctr suprvsn norm 1st preg unsp  |
| N76.0 Acute vaginitis □ N95.2 Postmenopausal atrophic vag. □  | Z34.83 Enctr suprvn norm preg, 3rd tri.  | Z34.80 Enctr suprvsn norm preg usp  |
|   | Z01.411 Enctr Gyn (gnrl) w/abnl. finding<br>Z01.419 Enctr Gyn (gnrl) w/o abnl finding  | ☐ Z77.21 Cont. w Exp. to pot. hazard fl. ☐ Z91.89 Other personal risk factors   |
| □ N76.3 Subacute and chronic vulvitis □ Z34.01 Enctr suprvn norm 1st preg, 1st □  | Z11.51 Enctr for screen HPV  | Z13.71 Nonprocreative screening for genetic disease carrier status  |
|   | Z11.3 Enctr screen infect w/sex transmiss<br>Z12.4 Enctr screen malig. neo. cervix   | Z31.430 Female for testing for genetic disease carrier status for procreative mgmt  |
|   | Other:   | Other:  |
|   | ATION (Check all that apply)   |   |
| ,   |  | ☐ IUD ☐ Postpartum ☐ Supracervical Hysterectomy   |
| ASCUS   LGSIL   ASC-H   HGSIL   AGC   Method?   Histo   | ory of Radiation  Hysterectomy   | Post Menopausal Pregnant Other:   |
| GYN CYTOLOGY & MOLECULAR  | MOLECULAR TESTS AND PANELS   | GYNECOLOGIC HISTOLOGY   |
| SPECIMEN SOURCE: LMP or Menopause Date:   | STD TESTING  Leukorrhea Panel (CT/NG/TV)   | ☐ A. Cervical Biopsy ☐ H. Perineum Biopsy   |
| ☐ Cervix/Endocervix ☐ Vagina ☐ Oral ☐ Anal  |  |   |
| Pap Test (follow provider-driven rules on file)   | , , , , , , , , , , , , , , , , , ,  | ☐ B. Endocervical Curetting - ECC ☐ I. Other  |
| O Disrogard provider driven rules   | ☐ Leukorrhea Extended Panel ☐ Chlamydia trachomatis (NAAT)   | □ B. Endocervical Curetting - ECC □ I. Other □ C. LEEP  |
| O Disregard provider-driven rules   | Leukorrhea Extended Panel  | □ B. Endocervical Curetting - ECC □ I. Other □ C. LEEP □ D. Cervical Cone   |
| <ul> <li>○ Disregard provider-driven rules</li> <li>□ Pap Test: Reflex to High-risk HPV Onclarity if Pap:</li> <li>○ ASC-US</li> </ul>  | ☐ Leukorrhea Extended Panel ☐ Chlamydia trachomatis (NAAT) ☐ Neisseria gonorrhoeae (NAAT) ☐ Trichomonas vaginalis (NAAT)   | □ B. Endocervical Curetting - ECC     □ I. Other       □ C. LEEP     □       □ D. Cervical Cone     □       □ E. Endometrial Biopsy - EMB     □ J. Other  |
| Pap Test: Reflex to High-risk HPV Onclarity if Pap:   | ☐ Leukorrhea Extended Panel ☐ Chlamydia trachomatis (NAAT) ☐ Neisseria gonorrhoeae (NAAT) ☐ Trichomonas vaginalis (NAAT) ☐ Herpes Simplex Virus 1 & 2 (NAAT)   | □ B. Endocervical Curetting - ECC       □ I. Other         □ C. LEEP  |
| Pap Test: Reflex to High-risk HPV Onclarity if Pap:  ASC-US   | ☐ Leukorrhea Extended Panel ☐ Chlamydia trachomatis (NAAT) ☐ Neisseria gonorrhoeae (NAAT) ☐ Trichomonas vaginalis (NAAT)   | □ B. Endocervical Curetting - ECC       □ I. Other         □ C. LEEP       □         □ D. Cervical Cone       □         □ E. Endometrial Biopsy - EMB       □ J. Other         □ F. Vaginal Biopsy       □         □ G. Vulvar Biopsy       □   |
| ☐ Pap Test: Reflex to High-risk HPV Onclarity if Pap:   | □ Leukorrhea Extended Panel □ Chlamydia trachomatis (NAAT) □ Neisseria gonorrhoeae (NAAT) □ Trichomonas vaginalis (NAAT) □ Herpes Simplex Virus 1 & 2 (NAAT) □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING  | □ B. Endocervical Curetting - ECC       □ I. Other         □ C. LEEP  |
| <ul> <li>□ Pap Test: Reflex to High-risk HPV Onclarity if Pap:</li> <li>○ ASC-US</li> <li>○ ASC-US or above</li> <li>□ Pap &amp; High-risk HPV Onclarity*</li> <li>□ Pap, High-risk HPV Onclarity*, Chlamydia &amp; N. gonorrhoeae (NAAT)</li> <li>□ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae &amp; Trichomonas vaginalis (NAAT)</li> </ul>   | □ Leukorrhea Extended Panel □ Chlamydia trachomatis (NAAT) □ Neisseria gonorrhoeae (NAAT) □ Trichomonas vaginalis (NAAT) □ Herpes Simplex Virus 1 & 2 (NAAT) □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)  | □ B. Endocervical Curetting - ECC       □ I. Other         □ C. LEEP       □         □ D. Cervical Cone       □         □ E. Endometrial Biopsy - EMB       □ J. Other         □ F. Vaginal Biopsy       □         □ G. Vulvar Biopsy       □         □ labia majora       □ labia minora                                 |
| ☐ Pap Test: Reflex to High-risk HPV Onclarity if Pap:   | □ Leukorrhea Extended Panel □ Chlamydia trachomatis (NAAT) □ Neisseria gonorrhoeae (NAAT) □ Trichomonas vaginalis (NAAT) □ Herpes Simplex Virus 1 & 2 (NAAT) □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING  | □ B. Endocervical Curetting - ECC       □ I. Other         □ C. LEEP       □         □ D. Cervical Cone       □         □ E. Endometrial Biopsy - EMB       □ J. Other         □ F. Vaginal Biopsy       □         □ G. Vulvar Biopsy       □         □ labia majora       □ labia minora         □ rash       □ neoplasm |
| <ul> <li>□ Pap Test: Reflex to High-risk HPV Onclarity if Pap:</li> <li>○ ASC-US</li> <li>○ ASC-US or above</li> <li>□ Pap &amp; High-risk HPV Onclarity*</li> <li>□ Pap, High-risk HPV Onclarity*, Chlamydia &amp; N. gonorrhoeae (NAAT)</li> <li>□ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae &amp; Trichomonas vaginalis (NAAT)</li> <li>*Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups</li> </ul>  | □ Leukorrhea Extended Panel □ Chlamydia trachomatis (NAAT) □ Neisseria gonorrhoeae (NAAT) □ Trichomonas vaginalis (NAAT) □ Herpes Simplex Virus 1 & 2 (NAAT) □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms) □ Aerobic Vaginitis Panel  | □ B. Endocervical Curetting - ECC       □ I. Other         □ C. LEEP       □         □ D. Cervical Cone       □         □ E. Endometrial Biopsy - EMB       □ J. Other         □ F. Vaginal Biopsy       □         □ G. Vulvar Biopsy       □         □ labia majora       □ labia minora         □ rash       □ neoplasm |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap:   ○ ASC-US   ○ ASC-US or above □ Pap & High-risk HPV Onclarity* □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT) □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT) *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66).   | □ Leukorrhea Extended Panel     □ Chlamydia trachomatis (NAAT)     □ Neisseria gonorrhoeae (NAAT)     □ Trichomonas vaginalis (NAAT)     □ Herpes Simplex Virus 1 & 2 (NAAT)     □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)     □ Aerobic Vaginitis Panel     □ Bacterial Vaginitis Panel     □ Candidiasis Panel     □ Cervicitis/Vaginitis Panel   | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap: ○ ASC-US ○ ASC-US or above □ Pap & High-risk HPV Onclarity* □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT) □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT) *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66). □ Dtex Cervical FISH Test ○ Reflex if Pap ASC-US/High-risk HPV Positive ○ Reflex if Pap LSIL:   | □ Leukorrhea Extended Panel     □ Chlamydia trachomatis (NAAT)     □ Neisseria gonorrhoeae (NAAT)     □ Trichomonas vaginalis (NAAT)     □ Herpes Simplex Virus 1 & 2 (NAAT)     □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)     □ Aerobic Vaginitis Panel     □ Bacterial Vaginitis Panel     □ Candidiasis Panel     □ Cervicitis/Vaginitis Panel     □ Genital Ulcer Panel   | □ B. Endocervical Curetting - ECC       □ I. Other         □ C. LEEP       □         □ D. Cervical Cone       □         □ E. Endometrial Biopsy - EMB       □ J. Other         □ F. Vaginal Biopsy       □         □ G. Vulvar Biopsy       □         □ labia majora       □ labia minora         □ rash       □ neoplasm |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap:   ○ ASC-US   ○ ASC-US or above   □ Pap & High-risk HPV Onclarity*   □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT)   □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT)   *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66).   □ Dtex Cervical FISH Test   ○ Reflex if Pap ASC-US/High-risk HPV Positive   | □ Leukorrhea Extended Panel     □ Chlamydia trachomatis (NAAT)     □ Neisseria gonorrhoeae (NAAT)     □ Trichomonas vaginalis (NAAT)     □ Herpes Simplex Virus 1 & 2 (NAAT)     □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)     □ Aerobic Vaginitis Panel     □ Bacterial Vaginitis Panel     □ Candidiasis Panel     □ Cervicitis/Vaginitis Panel     □ Genital Ulcer Panel     □ Mycoplasma Panel  | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap: ○ ASC-US ○ ASC-US or above □ Pap & High-risk HPV Onclarity* □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT) □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT) *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66). □ Dtex Cervical FISH Test ○ Reflex if Pap ASC-US/High-risk HPV Positive ○ Reflex if Pap LSIL:   | □ Leukorrhea Extended Panel     □ Chlamydia trachomatis (NAAT)     □ Neisseria gonorrhoeae (NAAT)     □ Trichomonas vaginalis (NAAT)     □ Herpes Simplex Virus 1 & 2 (NAAT)     □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)     □ Aerobic Vaginitis Panel     □ Bacterial Vaginitis Panel     □ Candidiasis Panel     □ Cervicitis/Vaginitis Panel     □ Genital Ulcer Panel   | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap: ○ ASC-US ○ ASC-US or above □ Pap & High-risk HPV Onclarity* □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT) □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT) *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66). □ Dtex Cervical FISH Test ○ Reflex if Pap ASC-US/High-risk HPV Positive ○ Reflex if Pap LSIL: □ HPV Primary Screen  MEDICARE - Patients with screening Paps must sign ABN on the back page. HPV every 5 years. □ Medicare Screening Pap, Low-risk, Cervical - 2 yrs. Dx: Z12.4  | □ Leukorrhea Extended Panel     □ Chlamydia trachomatis (NAAT)     □ Neisseria gonorrhoeae (NAAT)     □ Trichomonas vaginalis (NAAT)     □ Herpes Simplex Virus 1 & 2 (NAAT)     □ Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)     □ Aerobic Vaginitis Panel     □ Bacterial Vaginitis Panel     □ Candidiasis Panel     □ Cervicitis/Vaginitis Panel     □ Genital Ulcer Panel     □ Mycoplasma Panel     □ PID/Infertility Panel  | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap: ○ ASC-US ○ ASC-US or above □ Pap & High-risk HPV Onclarity* □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT) □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT) *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66). □ Dtex Cervical FISH Test ○ Reflex if Pap ASC-US/High-risk HPV Positive ○ Reflex if Pap LSIL: □ HPV Primary Screen  MEDICARE - Patients with screening Paps must sign ABN on the back page. HPV every 5 years. □ Medicare Screening Pap, Low-risk, Cervical - 2 yrs. Dx: Z12.4 □ Medicare Screening Pap, Low-risk, Vagina - 2 yrs. Dx: Z12.72   | Leukorrhea Extended Panel    Chlamydia trachomatis (NAAT)   Neisseria gonorrhoeae (NAAT)   Trichomonas vaginalis (NAAT)   Herpes Simplex Virus 1 & 2 (NAAT)   Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)   Aerobic Vaginitis Panel   Bacterial Vaginitis Panel   Candidiasis Panel   Cervicitis/Vaginitis Panel   Genital Ulcer Panel   Mycoplasma Panel   PID/Infertility Panel   Standard Panel   Ureaplasma   UTI Complete™ Panel by RT-PCR   | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap:   ○ ASC-US   ○ ASC-US or above □ Pap & High-risk HPV Onclarity* □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT) □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT) *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66). □ Dtex Cervical FISH Test   ○ Reflex if Pap ASC-US/High-risk HPV Positive   ○ Reflex if Pap LSIL: □ HPV Primary Screen  MEDICARE - Patients with screening Paps must sign ABN on the back page. HPV every 5 years. □ Medicare Screening Pap, Low-risk, Cervical - 2 yrs. Dx: Z12.4 □ Medicare Screening Pap, Routine Exam, 2 yrs. Dx: Z01.419 □ Medicare Screening Pap, Routine Exam, w/abnormal findings - 2 yrs. Dx: Z01.411  | Leukorrhea Extended Panel    Chlamydia trachomatis (NAAT)   Neisseria gonorrhoeae (NAAT)   Trichomonas vaginalis (NAAT)   Herpes Simplex Virus 1 & 2 (NAAT)   Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)   Aerobic Vaginitis Panel   Bacterial Vaginitis Panel   Candidiasis Panel   Cervicitis/Vaginitis Panel   Genital Ulcer Panel   Mycoplasma Panel   PID/Infertility Panel   Standard Panel   Ureaplasma   UTI Complete™ Panel by RT-PCR   Vaginosis/Vaginitis Panel   | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap:   ○ ASC-US   ○ ASC-US or above □ Pap & High-risk HPV Onclarity* □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT) □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT) *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66). □ Dtex Cervical FISH Test   ○ Reflex if Pap ASC-US/High-risk HPV Positive   ○ Reflex if Pap LSIL: □ HPV Primary Screen  MEDICARE - Patients with screening Paps must sign ABN on the back page. HPV every 5 years. □ Medicare Screening Pap, Low-risk, Cervical - 2 yrs. Dx: Z12.4 □ Medicare Screening Pap, Routine Exam - 2 yrs. Dx: Z01.419  | Leukorrhea Extended Panel  Chlamydia trachomatis (NAAT)  Neisseria gonorrhoeae (NAAT)  Trichomonas vaginalis (NAAT)  Herpes Simplex Virus 1 & 2 (NAAT)  Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)  Aerobic Vaginitis Panel  Bacterial Vaginitis Panel  Candidiasis Panel  Cervicitis/Vaginitis Panel  Genital Ulcer Panel  Mycoplasma Panel  PID/Infertility Panel  Standard Panel  Ureaplasma  UTI Complete™ Panel by RT-PCR  Vaginosis/Vaginitis Panel  Vaginosis/Vaginitis Extended Panel                          | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| □ Pap Test: Reflex to High-risk HPV Onclarity if Pap:   ○ ASC-US   ○ ASC-US or above □ Pap & High-risk HPV Onclarity* □ Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT) □ Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT) *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66). □ Dtex Cervical FISH Test   ○ Reflex if Pap ASC-US/High-risk HPV Positive   ○ Reflex if Pap LSIL: □ HPV Primary Screen  MEDICARE - Patients with screening Paps must sign ABN on the back page. HPV every 5 years. □ Medicare Screening Pap, Low-risk, Cervical - 2 yrs. Dx: Z12.4 □ Medicare Screening Pap, Routine Exam, 2 yrs. Dx: Z01.419 □ Medicare Screening Pap, Routine Exam, w/abnormal findings - 2 yrs. Dx: Z01.411  | Leukorrhea Extended Panel  Chlamydia trachomatis (NAAT)  Neisseria gonorrhoeae (NAAT)  Trichomonas vaginalis (NAAT)  Herpes Simplex Virus 1 & 2 (NAAT)  Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)  Aerobic Vaginitis Panel  Bacterial Vaginitis Panel  Candidiasis Panel  Cervicitis/Vaginitis Panel  Genital Ulcer Panel  Mycoplasma Panel  PID/Infertility Panel  Standard Panel  Ureaplasma  UTI Complete™ Panel by RT-PCR  Vaginosis/Vaginitis Extended Panel  PERINATAL TESTING                                  | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| Pap Test: Reflex to High-risk HPV Onclarity if Pap:  ASC-US  ASC-US  ASC-US or above  Pap & High-risk HPV Onclarity*  Pap, High-risk HPV Onclarity*, <i>Chlamydia &amp; N. gonorrhoeae</i> (NAAT)  Pap, High-risk HPV Onclarity*, <i>Chlamydia, N. gonorrhoeae &amp; Trichomonas vaginalis</i> (NAAT)  *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66).  Dtex Cervical FISH Test  Reflex if Pap ASC-US/High-risk HPV Positive  Reflex if Pap LSIL:  HPV Primary Screen  MEDICARE - Patients with screening Paps must sign ABN on the back page. HPV every 5 years.  Medicare Screening Pap, Low-risk, Cervical - 2 yrs. Dx: Z12.4  Medicare Screening Pap, Routine Exam - 2 yrs. Dx: Z01.419  Medicare Screening Pap, Routine Exam, w/abnormal findings - 2 yrs. Dx: Z01.411  Medicare Screening Pap, High-risk, Medical Hx - 1 yr. Dx: Z91.89  | Leukorrhea Extended Panel  Chlamydia trachomatis (NAAT)  Neisseria gonorrhoeae (NAAT)  Trichomonas vaginalis (NAAT)  Herpes Simplex Virus 1 & 2 (NAAT)  Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)  Aerobic Vaginitis Panel  Bacterial Vaginitis Panel  Candidiasis Panel  Cervicitis/Vaginitis Panel  Genital Ulcer Panel  Mycoplasma Panel  PID/Infertility Panel  Standard Panel  Ureaplasma  UTI Complete™ Panel by RT-PCR  Vaginosis/Vaginitis Extended Panel  PERINATAL TESTING  Group B Streptococcus by RT-PCR | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| Pap Test: Reflex to High-risk HPV Onclarity if Pap:  ASC-US  ASC-US  ASC-US or above  Pap & High-risk HPV Onclarity*  Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT)  Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT)  *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66).  Dtex Cervical FISH Test  Reflex if Pap ASC-US/High-risk HPV Positive  Reflex if Pap LSIL:  HPV Primary Screen  MEDICARE - Patients with screening Paps must sign ABN on the back page. HPV every 5 years.  Medicare Screening Pap, Low-risk, Cervical - 2 yrs. Dx: Z12.4  Medicare Screening Pap, Routine Exam - 2 yrs. Dx: Z01.419  Medicare Screening Pap, Routine Exam, w/abnormal findings - 2 yrs. Dx: Z01.411  Medicare Screening Pap, High-risk, Medical Hx - 1 yr. Dx: Z91.89  OTHER CYTOLOGY  | Leukorrhea Extended Panel  Chlamydia trachomatis (NAAT)  Neisseria gonorrhoeae (NAAT)  Trichomonas vaginalis (NAAT)  Herpes Simplex Virus 1 & 2 (NAAT)  Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)  Aerobic Vaginitis Panel  Bacterial Vaginitis Panel  Candidiasis Panel  Cervicitis/Vaginitis Panel  Genital Ulcer Panel  Mycoplasma Panel  PID/Infertility Panel  Standard Panel  Ureaplasma  UTI Complete™ Panel by RT-PCR  Vaginosis/Vaginitis Extended Panel  PERINATAL TESTING                                  | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |
| Pap Test: Reflex to High-risk HPV Onclarity if Pap:  ASC-US ASC-US or above  Pap & High-risk HPV Onclarity*  Pap, High-risk HPV Onclarity*, Chlamydia & N. gonorrhoeae (NAAT)  Pap, High-risk HPV Onclarity*, Chlamydia, N. gonorrhoeae & Trichomonas vaginalis (NAAT)  *Test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66).  Dtex Cervical FISH Test  Reflex if Pap ASC-US/High-risk HPV Positive  Reflex if Pap LSIL:  HPV Primary Screen  MEDICARE - Patients with screening Paps must sign ABN on the back page. HPV every 5 years.  Medicare Screening Pap, Low-risk, Cervical - 2 yrs. Dx: Z12.4  Medicare Screening Pap, Low-risk, Vagina - 2 yrs. Dx: Z12.72  Medicare Screening Pap, Routine Exam - 2 yrs. Dx: Z01.419  Medicare Screening Pap, Routine Exam, w/abnormal findings - 2 yrs. Dx: Z01.411  Medicare Screening Pap, High-risk, Medical Hx - 1 yr. Dx: Z91.89  OTHER CYTOLOGY  SPECIMEN SOURCE: Right Breast Left Breast Anal | Leukorrhea Extended Panel  Chlamydia trachomatis (NAAT)  Neisseria gonorrhoeae (NAAT)  Trichomonas vaginalis (NAAT)  Herpes Simplex Virus 1 & 2 (NAAT)  Treponema pallidum (Syphilis)  SYMPTOMATIC TESTING (see reverse for panel organisms)  Aerobic Vaginitis Panel  Bacterial Vaginitis Panel  Candidiasis Panel  Cervicitis/Vaginitis Panel  Genital Ulcer Panel  Mycoplasma Panel  PID/Infertility Panel  Standard Panel  UTI Complete™ Panel by RT-PCR  Vaginosis/Vaginitis Extended Panel  PERINATAL TESTING  Group B Streptococcus by RT-PCR             | □ B. Endocervical Curetting - ECC □ I. Other   □ C. LEEP □   □ D. Cervical Cone □   □ E. Endometrial Biopsy - EMB □ J. Other   □ F. Vaginal Biopsy □   □ G. Vulvar Biopsy □   □ labia majora □ labia minora   □ rash □ neoplasm   Relevant clinical description or history:   |



## **Bellingham Laboratory** 3560 Meridian Street, Suite 101

Bellingham, WA 98225

listed above. I understand with this choice I am **not** 

**Dallas Laboratory** 6221 Riverside Drive, Suite 119 Irving, TX 75039

|  | 360.527.4580   | 877.232.9924  |
|--|--|---|
| A. Notifier:   |  | verodx.com  |
| B. Patient Name:   | C. Identification Number:                              |   |
| ADVANCE BENEFICI   | ARY NOTICE OF NON-COVERAGE (ABN)                       |   |
| NOTE: If Medicare doesn't pay for D<br>Medicare does not pay for everything, even some care that you or y  | our health care provider have good reason to think you | y, you may have to pay.<br>need. We expect Medicare may |
| not pay for the <b>D.</b>  | below  | 1.  |
| D.   | E. Reason Medicare May Not Pay                         | F. Estimated Cost                                       |
|  |  |   |
| <ul> <li>WHAT YOU NEED TO DO NOW:</li> <li>Read this notice, so you can make an informed decision about</li> <li>Ask us any questions that you may have after you finish readir</li> <li>Choose an option below about whether to receive the D</li> <li>Note: If you choose Option 1 or 2, we may help you to use any</li> </ul> | ng.  | listed above.<br>not require us to do this.             |
| G. OPTIONS: Check only one box. We cannot choose a box for y   | ou.  |   |
| OPTION 1. I want the D.  Medicare billed for an official decision on payment, which is so pay, I am responsible for payment, but I can appeal to Medical payments I made to you, less co-pays or deductibles.  | ent to me on a Medicare Summary Notice (MSN). I under  | rstand that if Medicare doesn't                         |
| OPTION 2. I want the D   |  | bill Medicare. You may ask to be                        |

## H. ADDITIONAL INFORMATION:

OPTION 3. I don't want the D. \_

 $responsible \ for \ payment, \ and \ I \ cannot \ appeal \ to \ see \ if \ Medicare \ would \ pay.$ 

This notice gives our opinion, not an official Medicare decision. If you have other questions on this notice or Medicare billing, call 1-800-MEDICARE (1-800-633-4227 / TTY: 1-877-486-2048). Signing below means that you have received and understand this notice. You also receive a copy.

| I. Signature | J. Date |
|--------------|---------|
|              |         |
|              |         |

You have the right to get Medicare information in an accessible format, like large print, Braille, or audio. You also have the right to file a complaint if you feel you've been discriminated against. Visit Medicare.gov/about-us/accessibility-nondiscrimination-notice.

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0566. The time required to complete this information collection is estimated to average 7 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Baltimore, Maryland 21244-1850.

| Form CMS-R-131 (Exp. 01/31/2026) |   |                                       | Form Approved OMB No. 0938-0566  |
|----------------------------------|---|---------------------------------------|--|
|                                  | SYMPTOMATIC TESTI   | NG PANEL ORGANIS                      | MS   |
| Leukorrhea Panel                 | Chlamydia trachomatis, Neisseria gonorrhoeae,<br>Trichomonas vaginalis  | Standard Panel                        | Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus<br>jensenii, Gardnerella vaginalis, Atopobium vaginae,<br>Megasphaera spp. Type I, BVAB2, Candida albicans,<br>Candida glabrata  |
| Leukorrhea<br>Extended Panel     | Chlamydia trachomatis, Neisseria gonorrhoeae,<br>Trichomonas vaginalis, Mycoplasma genitalium   |                                       |  |
|                                  |   | Ureaplasma                            | Ureaplasma urealyticum   |
| Aerobic Vaginitis Panel          | Staphylococcus aureus, Streptococcus agalactiae (group B), Enterococcus faecalis, Escherichia coli  | UTI Complete™ Panel                   | anel Acinetobacter baumannii, Actinobaculum schaalii, Aerococcus urinae, Alloscardovia Omnicolens, Candida   |
| Bacterial Vaginosis Panel        | Gardnerella vaginalis, Atopobium vaginae,<br>Megasphaera spp. Type I, BVAB2, Mobiluncus<br>curtisii, Mobiluncus mulieris, Lactobacillus crispatus,<br>Lactobacillus gasseri, Lactobacillus jensenii |                                       | albicans, Candida auris, Candida glabrata, Candida<br>parapsilosis, Citrobacter freundii, Citrobacter koseri,<br>Coagulase Negative Staph, Corynebacterium riegelii,<br>Enterobacter aerogenes, Enterobacter cloacae,  |
| Candidiasis Panel                | Candida albicans, Candida tropicalis, Candida<br>parapsilosis, Candida glabrata, Candida krusei   |                                       | Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Mycoplasma hominis, Pantoea agglomerans, Proteus mirabilis, Proteus vulgaris, Providencia stuarti, Pseudomonas aeruginosa, Serratia marcescens, |
| Cervicitis/Vaginitis Panel       | Leukorrhea Panel, Bacterial Vaginitis Panel, Candidiasis<br>Panel, Mycoplasma Panel, Ureaplasma   |                                       |  |
| Genital Ulcer Panel              | Herpes Simplex Virus 1 & 2, Haemophilus ducreyi<br>(chancroid), Treponema pallidum (syphilis)   |                                       | Staphylococcus aureus, Streptococcus agalactiae,<br>Ureaplasma urealyticum, Viridans Group Strep   |
| Mycoplasma Panel                 | Mycoplasma hominis, Mycoplasma genitalium   | Vaginosis/Vaginitis Panel             | Trichomonas vaginalis (NAAT), Bacterial Vaginitis Panel,<br>Candidiasis Panel  |
|                                  | . , , , ,   |                                       |  |
| PID/Infertility Panel            | Leukorrhea Panel, Bacterial Vaginitis Panel,<br>Mycoplasma Panel, Ureaplasma  | Vaginosis/Vaginitis<br>Extended Panel | Leukorrhea Panel, Bacterial Vaginitis Panel, Candidiasis<br>Panel  |